donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > NTRA Natera > Key Indicators
NTRA Natera
41.380
+2.530+6.51%
Post Mkt Price
41.38000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
3.19% 83.2142 -13.82% 65.2113 -13.82% 65.2113 -1.16% 78.3984
Receivable Turnover(T)
-13.28% 5.2251 5.18% 6.2349 5.18% 6.2349 11.69% 6.2382
Inventory Turnover(T)
22.21% 14.5645 8.02% 13.567 8.02% 13.567 2.62% 11.7431
Fixed Assets Turnover(T)
-11.17% 5.7411 -9.2% 6.9779 -9.2% 6.9779 -7.27% 7.2651
Total Asset Rate(T)
5.82% 0.6548 11.74% 0.5768 11.74% 0.5768 -7.43% 0.4937
ROIC
-47.32% -63.529% -37.28% -51.231% -37.28% -51.231% -21.92% -41.296%
ROE
-46.06% -119.473% -37.83% -82.791% -37.83% -82.791% -3.62% -62.943%
ROA
-50.78% -53.622% -43.42% -43.503% -43.42% -43.503% -28.22% -35.625%
Efficiency Ratios
ROE 5 Year Average
-- -- -1.02% -336.599% -- -- -- --
ROA 5 Year Average
-- -- -1.43% -46.105% -- -- -- --
Average 5 Years ROIC
-- -- -0.32% -59.503% -- -- -- --
Profitability Ratios TTM
Gross Margin
-6.01% 46.828% 2.44% 49.093% 2.44% 49.093% 3.53% 49.688%
Operating Margin
-49.39% -81.265% -35.32% -74.850% -35.32% -74.850% -45.58% -71.255%
Net Margin
-42.49% -81.890% -28.35% -75.416% -28.35% -75.416% -38.51% -72.156%
EBITDA Margin
-51.25% -0.7877% -37.06% -0.7219% -37.06% -0.7219% -47.88% -0.6828%
R & D Expense Ratio
68.03% 45.620% 65.13% 42.240% 65.13% 42.240% 74.26% 39.800%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-27.6% 64.201% 13.58% 52.262% 13.58% 52.262% 4.77% 43.276%
Total Assets to Common Equity
-12.02% 211.062% -1.27% 189.267% -1.27% 189.267% -5.19% 172.773%
Debt to Asset Ratio
-28.29% 74.396% 5.18% 60.804% 5.18% 60.804% -2.03% 50.782%
Current Ratio
-10.5% 4.2421 15.2% 4.9925 15.2% 4.9925 27.54% 5.9646
Quick Ratio
-10.32% 3.9807 15.48% 4.7332 15.48% 4.7332 26.36% 5.6787
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- 50.6% 34.398% -- -- -- --
Revenue CAGR(5Y)
-- -- 52.23% 23.572% -- -- -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company’s algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual’s tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
CEO: --
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...